Search

Your search keyword '"Medici, Federica"' showing total 8 results
Start Over Author "Medici, Federica" Publisher elsevier b.v.
8 results on '"Medici, Federica"'

1. Cost-effectiveness of the adherence with recommendations for clinical monitoring of patients with diabetes

Author

Bucci, Andrea, Carle, Flavia, Dajko, Marianxhela, Arcà, Silvia, Bellentani, Donata, Bruno, Velia, Carbone, Simona, Ceccolini, Carla, De Feo, Angela, Lispi, Lucia, Mariniello, Rosanna, Masullo, Maurizio, Medici, Federica, Pisanti, Paola, Visca, Modesta, Zanini, Rinaldo, Di Fiandra, Teresa, Magliocchetti, Natalia, Romano, Giovanna, Cantarutti, Anna, Corrao, Giovanni, Pugni, Pietro, Rea, Federico, Davoli, Marina, Di Martino, Mirko, Lallo, Adele, Vittori, Patrizia, Vuillermin, Giuliana, Bernardo, Alfonso, Fusciante, Anna, Belotti, Laura, De Palma, Rossana, Di Felice, Enza, Chiandetti, Roberta, Clagnan, Elena, Del Zotto, Stefania, Di Lenarda, Andrea, Mariotto, Aldo, Prezza, Marisa, Zanier, Loris, Fusco, Danilo, Marinacci, Chiara, Lora, Antonio, Merlino, Luca, Spazzafumo, Liana, Pizzi, Simone, Simiele, Maria, Massaro, Giuseppe, Attolini, Ettore, Lepore, Vito, Petrarolo, Vito, De Luca, Giovanni, Fantaci, Giovanna, Pollina Addario, Sebastiano, Scondotto, Salvatore, Bellomo, Francesco, Braga, Mario, Di Fabrizio, Valeria, Forni, Silvia, Francesconi, Paolo, Profili, Francesco, Avossa, Francesco, Corradin, Matteo, Vigna, Silvia, Dondi, Letizia, Martini, Nello, Pedrini, Antonella, Piccinni, Carlo, Cosentino, Mimma, Marvulli, Maria G., Maggioni, Aldo, Mancia, Giuseppe, and Perseghin, Gianluca

Published
2021
Full Text
View/download PDF

3. 1096: Classical prognostic factors outperform SUV-max in LACC: an observational study

Author

Medici, Federica, Castellucci, Paolo, Forlani, Ludovica, Ferioli, Martina, Arcelli, Alessandra, Malizia, Claudio, Vadalà, Maria, Dragonetti, Valentino, Monastero, Fabio, Laghi, Viola, Cilla, Savino, Buwenge, Milly, Macchia, Gabriella, Tagliaferri, Luca, Perrone, Anna Myriam, De Iaco, Pierandrea, Strigari, Lidia, Fanti, Stefano, and Morganti, Alessio Giuseppe

Published
2024
Full Text
View/download PDF

7. Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy.

Author

Zamboglou, Constantinos, Strouthos, Iosif, Sahlmann, Joerg, Farolfi, Andrea, Serani, Francesca, Medici, Federica, Cavallini, Letizia, Morganti, Alessio Guiseppe, Trapp, Christian, Koerber, Stefan A., Peeken, Jan C., Vogel, Marco M.E., Schiller, Kilian, Combs, Stephanie E., Eiber, Matthias, Vrachimis, Alexis, Ferentinos, Konstantinos, Spohn, Simon K.B., Kirste, Simon, and Gratzke, Christian

Subjects
*PROSTATE cancer, *PROSTATECTOMY, *ANDROGEN deprivation therapy, *RADIOTHERAPY, *METASTASIS, *RESEARCH, *ANTIANDROGENS, *RESEARCH methodology, *CANCER relapse, *RETROSPECTIVE studies, *PROSTATE, *RADIOISOTOPES, *EVALUATION research, *GALLIUM isotopes, *COMPARATIVE studies, *SALVAGE therapy, *PROSTATE tumors, *EMISSION-computed tomography, *MORSE Fall Scale
Abstract

Purpose: Prostate-specific membrane antigen positron emission tomography (PSMA-PET) is increasingly used to guide salvage radiation therapy (sRT) in patients with prostate cancer and biochemical recurrence/persistence after prostatectomy. This work examined (1) metastasis-free survival (MFS) after PSMA-PET guided sRT and (2) the metastatic patterns on PSMA-PET images after sRT.Methods and Materials: This retrospective, multicenter (9 centers, 5 countries) study included patients referred for PSMA-PET due to recurrent/persistent disease after prostatectomy. Patients with distant metastases (DM) on PSMA-PET before sRT were excluded. Cox regression was performed to assess the effect of clinical parameters on MFS. The distribution of PSMA-PET detected DM after sRT and their respective risk factors were analyzed.Results: All (n = 815) patients received intensity modulated RT to the prostatic fossa. In the case of PET-positive pelvic lymph nodes (PLN-PET) (n = 275, 34%), pelvic lymphatics had been irradiated. Androgen deprivation therapy had been given in 251 (31%) patients. The median follow-up after sRT was 36 months. The 2-/4-year MFS after sRT were 93%/81%. In multivariate analysis, the presence of PLN-PET was a strong predictor for MFS (hazard ratio, 2.39; P < .001). After sRT, DM were detected by PSMA-PET in 128/198 (65%) patients, and 2 metastatic patterns were observed: 43% had DM in sub-diaphragmatic para-aortic LNs (abdominal-lymphatic), 45% in bones, 9% in supra-diaphragmatic LNs, and 6% in visceral organs (distant). Two distinct signatures with risk factors for each pattern were identified.Conclusions: MFS in our study is lower compared with previous studies, obviously due to the higher detection rate of DM in PSMA-PET after sRT. Thus, it remains unclear whether MFS is a surrogate endpoint for overall survival in PSMA PET-staged patients in the post-sRT setting. PLN-PET may be proposed as a new surrogate parameter predictive of MFS. Analysis of recurrence patterns in PET after sRT revealed risk factor signatures for 2 metastatic patterns (abdominal-lymphatic and distant), which may allow individualized sRT concepts in the future. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results